Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Following a greenlight from the US FDA, Philips has enrolled the first patient in a trial of its newest intravascular ...

Heart disease is expected to affect 61% of US adults by 2050, so it’s important to know when problems may be afoot.

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

Learn about Peripheral Artery Disease (PAD) and its impact on the Black community. Discover the risks, symptoms, and treatment options for this irreversible medical condition.

Johnson & Johnson MedTech's Shockwave Medical unit today announced the first clinical outcomes associated with its Javelin ...

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a ...

Philips announced the first U.S. treatment using its new laser device that combines two peripheral artery disease (PAD) procedures into one.

Gains from its Bitcoin holdings contributed notably to EPS growth. Semler Scientific produces the QuantaFlo -- a non-invasive ...

Coronary artery disease is the silent killer because you can have it for years and have no symptoms until it’s too late.